Uniting industry experts dedicated to accelerating the frontier of transformative therapeutics, the 2nd Rare & Genetic Kidney Disease Drug Development Summit is the definitive industry forum sharing cross-industry insight to understand genetic drivers of disease, uncover early biomarkers of efficacy, and navigate disease specific endpoint development.

From clarifying molecular characteristics to reclassify disease subtypes to enrolling patient cohorts in rare disease populations, join industry experts in-person from Travere Therapeutics, FDA, Sanofi, Chinook Therapeutics, Goldfinch Bio, Takeda, Regulus Therapeutics, Otsuka and many more to accelerate life-changing therapeutics for the treatment of ADPKD, ARPKD, IgA, FSGS, Alport Syndrome.

To know more visit: https://ter.li/rzowfh